Navigation Links
BioElectronics Corporation's Commercial Resumes on Bloomberg Television
Date:7/15/2008

ActiPatch(TM) Brand and Product Awareness On the Increase

FREDERICK, Md., July 15 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the company will resume airing an investment and product-related commercial on financial network Bloomberg Television. CEO of BioElectronics, Andrew Whelan says, "We previously ran this commercial in April with significant success relating both to our equity and product awareness. We are excited to see these commercials airing again today and reaching millions of people."

ActiPatch(TM), the product marketed by BioElectronics Corp. is changing the face of medicine and the way we heal. Recently chosen as "One of 9 Medical Breakthroughs That May Change Your Life," by MedicalHeadway.com, ActiPatch(TM) is fast becoming the treatment of choice for everything from soft tissue injuries to surgical recovery.

ActiPatch(TM) is a drug-free wafer thin patch with an embedded battery- operated microchip that delivers weeks of continuous pulsed RF therapy for less than a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective, home use method that reduces soft tissue pain and swelling, and accelerates healing.

ActiPatch(TM) is very thin, easily applied and comfortable to wear on an injured area. The patch effectively minimizes pain and swelling. Physicians are so impressed with the power of the patch that they are providing it to their patients for uses beyond plastic surgery recovery.

Distribution has expanded into Canada, Italy, Switzerland, Denmark, Scandinavian countries, Singapore, Malaysia and India.

For more information visit http://www.bioelectronicscorp.com or call 866-757-2284.

About BioElectronics Corporation

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch(TM) is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch(TM) delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch(TM) is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international record for agencies.

Information on ActiPatch(TM) and BioElectronics Corporation is available at the following websites:
-- U.S. Consumer: http://www.actipatchonline.com

-- Podiatry: http://www.pemfpodiatry.com

-- Plastic Surgery: http://www.plasticsurgeryrelief.com and http://www.makemeheal.com

-- German orthopedic foot & ankle: http://www.diesfussexperten.de

-- Italy and Switzerland: http://www.actipatch.it

-- Canada: http://www.actipatchpaintherapy.ca

-- Netherlands: http://www.actipatch.de

-- Singapore & Malaysia: http://www.astonixlife.com/

-- BioElectronics Corp: http://www.bioelectronicscorp.com

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Media Relations Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email: pbaker@bigpictureagency.com

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email: jnoel701@yahoo.com


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. BioElectronics Corporation Receives 2007 Economic Development Innovator of the Year Award
2. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
3. BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11
4. BioElectronics Corporations New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide
5. BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond
6. BioElectronics Corporation Announces New Website for Italian Market
7. Nationally Recognized Corporations and Retailers Rally Behind breastcancer.org
8. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
9. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
10. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
11. OmniGuide Begins European Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Orion, MI (PRWEB) , ... March 24, 2017 ... ... insurance assistance, financial planning, and related services to families and business owners across ... initiative aimed at feeding regional families struggling with financial difficulties. , The Oxford/Orion ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge dentists, Dr. ... for sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, ... obstructive type, is increasingly being treated at dental offices with newly developed procedures ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/23/2017)... & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... health emergency and now estimates that there could be four million Zika-related cases in ... epidemics to date with numbers of US cases reported per year skyrocketing to an ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , Mar 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $3.5 billion ... and forecasts for all the given segments on global as well ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a ... an end-to-end supply chain management firm with expertise serving ... Product Solutions Rick Zaffarano was named a ... the Supply Chain by the only publication exclusively dedicated ... food supply chain. "Rick has brought to ...
(Date:3/23/2017)... SILVER SPRING, Md. , March 23, 2017 /PRNewswire-USNewswire/ ... approval to Bavencio (avelumab) for the treatment of adults ... Merkel cell carcinoma (MCC), including those who have not ... for metastatic MCC, a rare, aggressive form of skin ... the most common cancers, patients with a rare form ...
Breaking Medicine Technology: